Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
The FDA is pushing researchers to reduce their use of animal models and instead adopt ‘new approach methodologies’, like organoids and AI modelling. Here, Dr. Alaina Jaster speaks with psychedelic scientists and drug developers to unpack the debate.
Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics • Psilocybin Rescheduling Petition Heads to HHS • Sensorium Scores $25M Series A Extension to Take Kanna-Based Candidate Into Clinic • Researchers Call Lykos’ MDMA Pricing Modelling “Problematic” • Alabama Board of Medicine Issues Guidelines for Off-Label Ketamine in TRD • FDA Approves PharmaTher’s Ketamine After Two CRLs • Incannex Reports Positive Phase 2 Results for Psilocybin-Assisted Psychotherapy in GAD • and more..
AbbVie is set to buy Gilgamesh Pharmaceuticals’ lead candidate, GM-2505 (bretisilocin), in a deal worth up to $1.2bn. Here, we take a closer look at the acquisition, what it might tell us about big pharma’s interest in the field, and what it might mean for the broader crop of psychedelic drug developers…
This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine in treatment-resistant depression. Here, we break the news, dive deeper, and speak with insiders.
Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.
This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deeper into safety and efficacy data, the trial’s design and protocol, as well as the company’s plans for future development of the candidate in PPD and beyond.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from January 5 – June 1, 2025
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
This is an archived version of our Psychedelic News Feed, from February 5 2024 – March 3 2024.
This is an archived version of our Psychedelic News Feed, from January 8 2024 – February 4 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
